Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FYREMADEL vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Type 2 diabetes mellitus,Chronic weight management (off-label)
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
100 mg orally twice daily.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
FYREMADEL is metabolized via proteolytic cleavage by endogenous peptidases to smaller peptide fragments, not significantly metabolized by CYP450 enzymes.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
97% bound primarily to albumin and alpha-1-acid glycoprotein.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
0.8 L/kg (range 0.6–1.0 L/kg); indicates moderate tissue distribution.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 45% (range 35–55%) due to first-pass metabolism.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For GFR 30-89 m L/min: no adjustment; for GFR <30 m L/min: 50 mg orally twice daily.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg orally twice daily; Child-Pugh C: 50 mg orally twice daily.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Not established; use not recommended.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
No specific adjustment; monitor renal function.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). FYREMADEL is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), renal impairment (monitor renal function), hypersensitivity reactions, suicidal behavior or ideation (monitor), and increased heart rate.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Personal or family history of MTC or MEN 2, known serious hypersensitivity to FYREMADEL or any excipients, and pregnancy (due to fetal risk).
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Grapefruit and grapefruit juice may increase plasma concentrations of FYREMADEL due to CYP3A4 inhibition; avoid concurrent consumption. No other significant food interactions reported.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/third trimester: Increased risk of spontaneous abortion, fetal growth restriction, and oligohydramnios. Contraindicated throughout pregnancy.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
No human data on excretion in breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infants, including immunosuppression and growth retardation. Breastfeeding is contraindicated during therapy and for at least 7 days after last dose.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Contraindicated in pregnancy; no dose adjustments apply. If inadvertent exposure occurs, immediate discontinuation is required. No pharmacokinetic data for pregnancy due to contraindication.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
FYREMADEL is a selective dopamine D3 receptor antagonist used for the treatment of acute agitation in schizophrenia. Onset of action is within 15-20 minutes after intramuscular injection. Monitor for extrapyramidal symptoms, especially in elderly patients. Avoid use in patients with Parkinson's disease or Lewy body dementia due to potential worsening of motor symptoms. QT prolongation risk is minimal but caution with concomitant CYP3A4 inhibitors or known QT prolonging drugs.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
This medication is given as an injection into a muscle and will start to work quickly.,You may feel drowsy or dizzy after receiving this medication; do not drive or operate heavy machinery until the effects have worn off.,Report any muscle stiffness, restlessness, or uncontrolled movements to your healthcare provider immediately.,Avoid alcohol and other central nervous system depressants while taking this medication.,Inform your doctor if you have a history of heart problems, liver disease, or seizures.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FYREMADEL vs ALFENTANIL, answered by our medical review team.
FYREMADEL is a Opioid Analgesic that works by FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FYREMADEL and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FYREMADEL is: 100 mg orally twice daily.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FYREMADEL and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FYREMADEL is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/thi. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.